Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-08-09
2011-08-09
Stucker, Jeffrey (Department: 1649)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100, C435S328000, C435S335000
Reexamination Certificate
active
07994302
ABSTRACT:
The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.
REFERENCES:
patent: 5596072 (1997-01-01), Culpepper et al.
patent: 5652123 (1997-07-01), Caput et al.
patent: 5696234 (1997-12-01), Zurawski et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 5783181 (1998-07-01), Browne et al.
patent: 5830453 (1998-11-01), Badr et al.
patent: 5919456 (1999-07-01), Puri et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6143871 (2000-11-01), Bonnefoy et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6214559 (2001-04-01), Collins et al.
patent: 6248714 (2001-06-01), Collins et al.
patent: 6268480 (2001-07-01), Collins et al.
patent: 6407218 (2002-06-01), Tamarkin et al.
patent: 6468528 (2002-10-01), Mak et al.
patent: 6495331 (2002-12-01), Gelfand et al.
patent: 6511848 (2003-01-01), Jungfer et al.
patent: 6518061 (2003-02-01), Puri et al.
patent: 6599914 (2003-07-01), Schleimer et al.
patent: 6638621 (2003-10-01), Anderson
patent: 6656695 (2003-12-01), Berg et al.
patent: 6676939 (2004-01-01), Hurst et al.
patent: 6746839 (2004-06-01), Duff et al.
patent: 6811780 (2004-11-01), Furfine et al.
patent: 6824986 (2004-11-01), Finkelman et al.
patent: 7615213 (2009-11-01), Kasaian et al.
patent: 2002/0197266 (2002-12-01), Debinski
patent: 2003/0013851 (2003-01-01), Powers
patent: 2003/0031666 (2003-02-01), Debinski et al.
patent: 2003/0044975 (2003-03-01), Rossjohn et al.
patent: 2003/0118546 (2003-06-01), Wei et al.
patent: 2003/0129132 (2003-07-01), Puri et al.
patent: 2003/0129166 (2003-07-01), Suen et al.
patent: 2003/0134419 (2003-07-01), Steinman et al.
patent: 2003/0138433 (2003-07-01), Newell et al.
patent: 2003/0143199 (2003-07-01), Carson et al.
patent: 2003/0143658 (2003-07-01), Casella
patent: 2003/0165887 (2003-09-01), Reed
patent: 2003/0170203 (2003-09-01), Yu
patent: 2003/0175898 (2003-09-01), Pantelidis
patent: 2003/0180252 (2003-09-01), Tamarkin
patent: 2003/0211104 (2003-11-01), Furfine et al.
patent: 2003/0235555 (2003-12-01), Shealy et al.
patent: 2004/0023337 (2004-02-01), Heavner et al.
patent: 2004/0028650 (2004-02-01), Van Snick
patent: 2004/0030097 (2004-02-01), Serrano et al.
patent: 2004/0115194 (2004-06-01), Wang
patent: 2004/0234499 (2004-11-01), Shealy et al.
patent: 2004/0248260 (2004-12-01), Heavner et al.
patent: 2005/0065237 (2005-03-01), Schmidt
patent: 2005/0065327 (2005-03-01), Monk et al.
patent: 2005/0096268 (2005-05-01), Wynn
patent: 2005/0169901 (2005-08-01), Pang
patent: 2005/0266005 (2005-12-01), Heavner
patent: 2006/0024306 (2006-02-01), Strober et al.
patent: 2006/0063228 (2006-03-01), Kasaian et al.
patent: 2006/0073148 (2006-04-01), Tchistiakova et al.
patent: 2008/0171014 (2008-07-01), Wu et al.
patent: 0 506 574 (1992-03-01), None
patent: 0621341 (1994-04-01), None
patent: 0 463 151 (1996-06-01), None
patent: 1327681 (2003-07-01), None
patent: 3 068 180 (1991-03-01), None
patent: 3 086 506 (1991-03-01), None
patent: 3 086 507 (1991-03-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 94/04680 (1994-03-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/29417 (1996-09-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/15663 (1997-05-01), None
patent: WO 97/20926 (1997-06-01), None
patent: WO 98/10638 (1998-03-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/31384 (1998-07-01), None
patent: WO 00/40264 (2000-01-01), None
patent: WO 00/36103 (2000-06-01), None
patent: WO 00/62736 (2000-10-01), None
patent: WO 00/64944 (2000-11-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 01/08660 (2001-02-01), None
patent: WO 02/055100 (2002-07-01), None
patent: WO 02/056902 (2002-07-01), None
patent: WO 02/056905 (2002-07-01), None
patent: WO 02/085308 (2002-10-01), None
patent: WO 02/085309 (2002-10-01), None
patent: WO 02/100432 (2002-12-01), None
patent: WO 03/034984 (2003-05-01), None
patent: WO 03/035847 (2003-05-01), None
patent: WO 03/058201 (2003-07-01), None
patent: WO 03/068799 (2003-08-01), None
patent: WO 03/086451 (2003-10-01), None
patent: WO 03/090776 (2003-11-01), None
patent: WO 03/092610 (2003-11-01), None
patent: WO 2004/001655 (2003-12-01), None
patent: WO 2004/015070 (2004-02-01), None
patent: WO 2004/019974 (2004-03-01), None
patent: WO 2004/022096 (2004-03-01), None
patent: WO 2004/069274 (2004-08-01), None
patent: WO 2004/090539 (2004-10-01), None
patent: WO 2004/092404 (2004-10-01), None
patent: WO 2004/094458 (2004-11-01), None
patent: WO 2005/007699 (2005-01-01), None
patent: WO 2005062967 (2005-07-01), None
patent: WO 2005/091853 (2005-10-01), None
patent: WO 2006/003407 (2006-01-01), None
U.S. Appl. No. 10/058,393.
U.S. Appl. No. 07/466,008, filed Jan. 12, 1990.
U.S. Appl. No. 07/610,515, filed Nov. 8, 1990.
U.S. Appl. No. 07/919,297, filed Jul. 24, 1992.
U.S. Appl. No. 07/922,649, filed Jul. 30, 1992.
U.S. Appl. No. 08/031,801, filed Mar. 15, 1993.
U.S. Appl. No. 08/112,848, filed Aug. 27, 1993.
U.S. Appl. No. 08/234,145, filed Apr. 28, 1994.
U.S. Appl. No. 08/376,279, filed Jan. 20, 1995.
U.S. Appl. No. 08/430,938, filed Apr. 27, 1995.
U.S. Appl. No. 08/464,584, filed Jun. 5, 1995.
U.S. Appl. No. 08/464,582, filed Jun. 5, 1995.
U.S. Appl. No. 08/463,191, filed Jun. 5, 1995.
U.S. Appl. No. 08/462,837, filed Jun. 5, 1995.
U.S. Appl. No. 08/486,853, filed Jun. 5, 1995.
U.S. Appl. No. 08/486,859, filed Jun. 5, 1995.
U.S. Appl. No. 08/462,513, filed Jun. 5, 1995.
U.S. Appl. No. 08/724,752, filed Oct. 2, 1996.
U.S. Appl. No. 08/759,620, filed Dec. 3, 1996.
Bost, et al. “In Vivo Treatment with Anti-Interleukin-13 Antibodies Significantly Reduces the Humoral Immune Response Against an Oral Immunogen in Mice”Immuology, Blackwell Publishing, Oxford, GB, vol. 87, 1996, pp. 633-641.
Blease et al., “Therapeutic Effect of IL-13 Immunoneutralization During Chronic Experimental Fungal Asthma,”The Journal of Immunology, 5219-5224 (2001).
Green et al.,Nature Genetics7:13-21 (1994).
Heinzmann et al., “Genetic Variants of IL-13 Signalling and Human Asthma and Atopy”Human Molecular Genetics, vol. 9, No. 4, pp. 549-559, Oxford University Press (2000).
Tekkanat et al., “IL-13-Induced Airway Hyperreactivity During Respiratory Syncytial Virus Infection is STAT6 Dependent,”The Journal of Immunology3542-3548 (2001).
Yang, et al., “Anti-IL-13 Monoclonal Antibody Inhibits Airway Hyperresponsiveness, Inflammation and Airway Remodeling,”Cytokine28 224-232 (2004).
Skinnider, et al. “Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma”Blood, Jan. 1, 2001—vol. 97, No. 1 2001 by the American Society of Hematology.
Mckenzie, et al.. “Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function” Proc.Natl. Acad. Sci. USA vol. 90, pp. 3735-3739, Apr. 1993 Immunology.
Arima et al., “Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma,”J Allergy Clin Immunol109(6) pp. 980-987 (2002).
Babcook et al., “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities,”Proc. Natl. Acad. Sci. USA, 93:7843-7848 (1996).
Charman W.N. “
Ahluwalia Kiran
Faggioni Raffaella
Foltz Ian
Foord Orit
Kang Jaspal S.
Amgen Inc.
Gucker Stephen
Machin Nathan A.
Stucker Jeffrey
LandOfFree
Fully human monoclonal antibodies to IL-13 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fully human monoclonal antibodies to IL-13, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fully human monoclonal antibodies to IL-13 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747216